720 reports of this reaction
3.4% of all GRANISETRON reports
#3 most reported adverse reaction
FEBRILE NEUTROPENIA is the #3 most commonly reported adverse reaction for GRANISETRON, manufactured by Cumberland Pharmaceuticals Inc.. There are 720 FDA adverse event reports linking GRANISETRON to FEBRILE NEUTROPENIA. This represents approximately 3.4% of all 21,280 adverse event reports for this drug.
Patients taking GRANISETRON who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is moderately reported among GRANISETRON users, representing a notable but not dominant share of adverse events.
In addition to febrile neutropenia, the following adverse reactions have been reported for GRANISETRON:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 720 FDA reports for GRANISETRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 3.4% of all adverse event reports for GRANISETRON, making it one of the most commonly reported side effect.
If you experience febrile neutropenia while taking GRANISETRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.